(142) Erythrocyte membrane biomimetic nanoparticles for Dapagliflozin delivery in the fibrotic heart
Introduction: Myocardial infarction often causes cardiac insufficiency, leading to fibrosis and heart failure (HF) [1]. Gliflozins (e.g., Dapagliflozin), used for type 2 diabetes, showed promise in reducing cardiovascular death and hospitalization for HF [2]. They can improve fibrosis post-ischemia, but the mechanisms remain unclear, and potential side effects exist [3-4]. The use nanoparticles (NPs) as in situ injectable drug delivery systems offers potential advantages. This study aimed at developing erythrocytes membrane-based biomimetic NPs as a new tool for Dapagliflozin delivery in the fibrotic heart.
Learning Objectives:
Develop erythrocyte membrane-based biomimetic nanoparticles for Dapagliflozin delivery.
Use microfluidics to control NPs size and morphology, with enhanced stability and reproducibility.
Further investigate the biological activity of Dapagliflozin in heart fibrosis.
Luigia Serpico, MSc, DSc – Post Doc, Department of Biomaterials and Biomedical Technology (BBT), The University Medical Center Groningen (UMCG); Renata Patrícia Faria Maia, MSc – PhD student, Department of Biomaterials and Biomedical Technology (BBT), The University Medical Center Groningen (UMCG); Raquel Bártolo Moura Fernandes Vítor, MSc – PhD student, Department of Biomaterials and Biomedical Technology (BBT, The University Medical Center Groningen (UMCG); Zehua Liu, Msc, DSc – Post Doc, Department of Biomaterials and Biomedical Technology (BBT), The University Medical Center Groningen (UMCG); Hélder Almeida Santos, MSc, DSc – Full Professor and Head of Department, Department of Biomaterials and Biomedical Technology (BBT), The University Medical Center Groningen (UMCG)
